Breaking Medical
Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) to Release Fiscal Third Quarter Financial Results and Host
Conference Call on February 14, 2024
SAN DIEGO, CA, February
7, 2024 – (Investorideas.com Newswire) Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic
company focused on developing products to treat cancer and life threatening
infectious diseases, today announced that it will issue financial results for
its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday,
February 14, 2024.
Read this news,
featuring AEMD in full at https://www.investorideas.com/news/2024/02071AEMD-Q3-Fiancial-Results.asp
Management will
host a conference call on Wednesday, February 14, 2023 at 4:30 p.m. ET to
review financial results and recent corporate developments. Following
management’s formal remarks, there will be a question and answer session.
Interested
parties can register for the conference by navigating to https://dpregister.com/sreg/10186345/fb902976dd. Please note
that registered participants will receive their dial-in number upon
registration.
Interested
parties without internet access or unable to pre-register may dial in by
calling:
PARTICIPANT DIAL
IN (TOLL FREE): 1-844-836-8741
PARTICIPANT
INTERNATIONAL DIAL IN: 1-412-317-5442
All callers
should ask for the Aethlon Medical, Inc. conference call.
A replay of the
call will be available approximately one hour after the end of the call through
March 14, 2024. The replay can be accessed via Aethlon Medical’s website or by
dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada
toll free at 1-855-669-9658. The replay conference ID number is 7691190.
About Aethlon and the Hemopurifier®
Aethlon Medical
is a medical therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and harmful exosomes from blood utilizing its proprietary
lectin-based technology. This action has potential applications in cancer,
where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.
Additional
information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to successfully
complete development of the Hemopurifier and to successfully demonstrate the
utility of the Hemopurifier in cancer and infectious diseases and in the
transplant setting; the Company's ability to raise additional capital and to
maintain its Nasdaq listing; the Company's ability to successfully manufacture
the Hemopurifier in sufficient quantities for its clinical trials, and other potential
risks. The foregoing list of risks and uncertainties is illustrative, but is
not exhaustive. Additional factors that could cause results to differ
materially from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the fiscal year ended March 31, 2023, and in the Company's other
filings with the Securities and Exchange Commission, including its quarterly
Reports on Form 10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake any duty,
to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech
stock on Investorideas.com
More info on AEMD at
Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News
Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp
https://www.investorideas.com/About/Disclaimer.asp
Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech Industry
Stocks- investing ideas in biotechnology stocks, medical technology and life
sciences
Like Biotech Stocks? View our Biotech
Stocks Directory
Get News Alerts on Biotech Stocks
No comments:
Post a Comment